Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Marth

Showing results (141-150 of 237) with videos related to

Pageof 24
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 10, 2014
Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patientsAxel Muendlein, Michael Hubalek, Simone Geller-Rhomberg, et al.
Scientific Reports|April 1, 2026
Absence of synergistic effects by CDK12/13 inhibition in combination with cisplatin or olaparib in ovarian cancer cellsFrédéric R Santer, Lea Hovdar, Florian Handle, et al.
Cancer Research|May 13, 2010
E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancerDaniel Reimer, Michael Hubalek, Svenja Riedle, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Tumoral programmed cell death 1 (PD1) expression in endometrial carcinoma is a prognostic marker for patient outcomeBarin Feroz, Teresa L Pan, Katharina Leitner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Serum C-reactive protein as independent prognostic variable in patients with ovarian cancerLukas A Hefler, Nicole Concin, Gerda Hofstetter, et al.
Critical Reviews in Oncology/Hematology|May 19, 2026
First-Line Immunotherapy With or Without PARP Inhibitors in Advanced Ovarian Cancer: A Meta-Analysis including Bevacizumab Use, Molecular Status, and PD-L1 ExpressionClaudia Marchetti, Carolina Maria Sassu, Amedeo Cefaliello, et al.
Cancer Research|July 3, 2004
DNA hypomethylation and ovarian cancer biologyMartin Widschwendter, Guanchao Jiang, Christian Woods, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 26, 2004
Methylated DNA collected by tampons--a new tool to detect endometrial cancerHeidi Fiegl, Conny Gattringer, Andreas Widschwendter, et al.
Clinical Breast Cancer|June 30, 2009
Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?Michael Gnant, Peter Dubsky, Florian Fitzal, et al.
BMC Public Health|August 28, 2016
Pre-vaccine era cervical human papillomavirus infection among screening population of women in west AustriaWegene Borena, Margarethe Grünberger, Andreas Widschwendter, et al.
Pageof 24

Showing results (141-150 of 237) with videos related to

Sort By:
Pageof 24
European Journal of Cancer (Oxford, England : 1990)|June 10, 2014
Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patientsAxel Muendlein, Michael Hubalek, Simone Geller-Rhomberg, et al.
Scientific Reports|April 1, 2026
Absence of synergistic effects by CDK12/13 inhibition in combination with cisplatin or olaparib in ovarian cancer cellsFrédéric R Santer, Lea Hovdar, Florian Handle, et al.
Cancer Research|May 13, 2010
E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancerDaniel Reimer, Michael Hubalek, Svenja Riedle, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
Tumoral programmed cell death 1 (PD1) expression in endometrial carcinoma is a prognostic marker for patient outcomeBarin Feroz, Teresa L Pan, Katharina Leitner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Serum C-reactive protein as independent prognostic variable in patients with ovarian cancerLukas A Hefler, Nicole Concin, Gerda Hofstetter, et al.
Critical Reviews in Oncology/Hematology|May 19, 2026
First-Line Immunotherapy With or Without PARP Inhibitors in Advanced Ovarian Cancer: A Meta-Analysis including Bevacizumab Use, Molecular Status, and PD-L1 ExpressionClaudia Marchetti, Carolina Maria Sassu, Amedeo Cefaliello, et al.
Cancer Research|July 3, 2004
DNA hypomethylation and ovarian cancer biologyMartin Widschwendter, Guanchao Jiang, Christian Woods, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 26, 2004
Methylated DNA collected by tampons--a new tool to detect endometrial cancerHeidi Fiegl, Conny Gattringer, Andreas Widschwendter, et al.
Clinical Breast Cancer|June 30, 2009
Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?Michael Gnant, Peter Dubsky, Florian Fitzal, et al.
BMC Public Health|August 28, 2016
Pre-vaccine era cervical human papillomavirus infection among screening population of women in west AustriaWegene Borena, Margarethe Grünberger, Andreas Widschwendter, et al.
Pageof 24